Business Context and Reporting Period
Company: Inspire Medical Systems, Inc. (INS)
Filing Type: Form 8-K (Current Report)
Report Date: November 3, 2025
Reporting Period: Quarter ended September 30, 2025
This filing serves as a notification that the Company issued a press release announcing its financial results for the third quarter of 2025. The filing also discloses upcoming investor and analyst meetings scheduled for November and December 2025.
Key Financial Metrics
The provided text is a cover sheet and index for the Form 8-K. It references the press release (Exhibit 99.1) and presentation materials (Exhibit 99.2) containing the actual financial data but does not list specific figures within this document.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Note: Specific financial values must be retrieved from the attached Exhibit 99.1 (Press Release) or the Company's quarterly report.
Material Changes
The filing text does not contain specific data to compare current period results against prior periods. It only confirms the issuance of results for the quarter ended September 30, 2025.
Guidance, Outlook, and Risks
- Outlook/Events: The Company plans to participate in various meetings with investors and analysts during November and December 2025.
- Disclosure Status: The information in Items 2.02 and 7.01, including the press release and presentation materials, is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.
- Risks/Contingencies: No specific risks or contingencies are detailed in this cover document.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual Q3 2025 revenue, net income, and cash flow figures.
- Examine Exhibit 99.2 (Presentation Materials) for updated guidance and strategic outlook.
- Verify the specific dates and topics of the investor meetings scheduled for late 2025.
- Confirm the Company's status as an emerging growth company (indicated as checked in the filing).